Chiome Bioscience Inc. (4583.T)
JPY 272.0
(-3.2%)
JPY 272.0
(-3.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 593.73 Million JPY | 39.79% |
| 2022 | 424.72 Million JPY | -4.85% |
| 2021 | 446.39 Million JPY | 16.07% |
| 2020 | 384.58 Million JPY | 164.99% |
| 2019 | 145.13 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 486.9 Million JPY | -3.84% |
| 2024 Q1 | 506.36 Million JPY | -14.71% |
| 2023 FY | 593.73 Million JPY | 39.79% |
| 2023 Q2 | 540.92 Million JPY | 3.32% |
| 2023 Q1 | 523.54 Million JPY | 52354200.0% |
| 2023 Q3 | 542.17 Million JPY | 0.23% |
| 2023 Q4 | 593.73 Million JPY | 9.51% |
| 2022 Q3 | 431.07 Million JPY | 0.0% |
| 2022 Q4 | 1000.00 JPY | -100.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 81.714% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -836.322% |
| GNI Group Ltd. | 26.34 Billion JPY | 97.746% |
| Linical Co., Ltd. | 10.3 Billion JPY | 94.238% |
| Trans Genic Inc. | 3.81 Billion JPY | 84.427% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -0.598% |
| Soiken Holdings Inc. | 697.02 Million JPY | 14.819% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 80.345% |
| AnGes, Inc. | 2.78 Billion JPY | 78.715% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -15.6% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.343% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -68.067% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 64.014% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -25.696% |
| CanBas Co., Ltd. | 91.98 Million JPY | -545.444% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 45.709% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 26.684% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 86.043% |
| PeptiDream Inc. | 29.11 Billion JPY | 97.961% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -4.807% |
| Ribomic Inc. | 155.8 Million JPY | -281.063% |
| SanBio Company Limited | 2.25 Billion JPY | 73.669% |
| Healios K.K. | 11.28 Billion JPY | 94.739% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -136.293% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -60.903% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -145.854% |
| StemRIM | 187 Million JPY | -217.503% |
| CellSource Co., Ltd. | 677.73 Million JPY | 12.395% |
| FunPep Company Limited | 189.32 Million JPY | -213.606% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 0.54% |
| Stella Pharma Corporation | 1.44 Billion JPY | 58.872% |
| TMS Co., Ltd. | 97.68 Million JPY | -507.777% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -548.929% |
| Cuorips Inc. | 200.96 Million JPY | -195.446% |
| K Pharma,Inc. | 209.13 Million JPY | -183.9% |
| Takara Bio Inc. | 11.42 Billion JPY | 94.801% |
| ReproCELL Incorporated | 741.03 Million JPY | 19.878% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 35.303% |
| StemCell Institute Inc. | 3.85 Billion JPY | 84.58% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 34.642% |
| CellSeed Inc. | 301.04 Million JPY | -97.222% |